A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.

Trial Profile

A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Testosterone (Primary)
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 30 Mar 2010 Warner Chilcott added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 14 Feb 2008 The expected completion date for this trial is now 1 Jul 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top